MA29451B1 - Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme - Google Patents

Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Info

Publication number
MA29451B1
MA29451B1 MA30375A MA30375A MA29451B1 MA 29451 B1 MA29451 B1 MA 29451B1 MA 30375 A MA30375 A MA 30375A MA 30375 A MA30375 A MA 30375A MA 29451 B1 MA29451 B1 MA 29451B1
Authority
MA
Morocco
Prior art keywords
malaria
treatment
ferroquin
association
derivative
Prior art date
Application number
MA30375A
Other languages
English (en)
Inventor
Laurent Fraisse
Daniel Ter-Minassian
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29451B1 publication Critical patent/MA29451B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'INVENTION A POUR OBJET UNE ASSOCIATION, QUI COMPREND DE LA FERROQUINE, SOUS FORME DE BASE LIBRE, DE SEL, D'HYDRATE OU DE SOLVAT, ET UN DÉRIVÉ D'ARTÉMISININE. L'INVENTION A ÉGALEMENT POUR OBJET UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA FERROQUINE, SOUS FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, D'UN HYDRATE OU D'UN SOLVAT DE LA FERROQUINE, ET D'AU MOINS UN DÉRIVÉ D'ARTÉMISININE. L'INVENTION A AUSSI POUR OBJET L'UTILISATION D'UNE TELLE ASSOCIATION POUR LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ AU TRAITEMENT OU À LA PRÉVENTION DU PALUDISME. L'INVENTION A ENFIN POUR OBJET UN KIT POUR LE TRAITEMENT OU LA PRÉVENTION DU PALUDISME.
MA30375A 2005-04-20 2007-11-19 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme MA29451B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503932A FR2884715B1 (fr) 2005-04-20 2005-04-20 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Publications (1)

Publication Number Publication Date
MA29451B1 true MA29451B1 (fr) 2008-05-02

Family

ID=35385843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30375A MA29451B1 (fr) 2005-04-20 2007-11-19 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Country Status (30)

Country Link
US (1) US20120258945A1 (fr)
EP (1) EP1874293A1 (fr)
JP (1) JP5148478B2 (fr)
KR (1) KR20080009088A (fr)
CN (2) CN101163470A (fr)
AP (1) AP2782A (fr)
AR (1) AR054253A1 (fr)
AU (1) AU2006238506B2 (fr)
BR (1) BRPI0610851A2 (fr)
CA (1) CA2605385A1 (fr)
CR (1) CR9425A (fr)
DO (1) DOP2006000092A (fr)
EA (1) EA012630B1 (fr)
FR (1) FR2884715B1 (fr)
GT (1) GT200600157A (fr)
HN (1) HN2006015130A (fr)
IL (1) IL186048A0 (fr)
MA (1) MA29451B1 (fr)
MX (1) MX2007012645A (fr)
MY (1) MY145581A (fr)
NO (1) NO20075920L (fr)
NZ (1) NZ562117A (fr)
PA (1) PA8669801A1 (fr)
PE (2) PE20061314A1 (fr)
SG (1) SG161270A1 (fr)
TN (1) TNSN07359A1 (fr)
TW (1) TWI387456B (fr)
UA (1) UA96414C2 (fr)
WO (1) WO2006111647A1 (fr)
ZA (1) ZA200708800B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926993B1 (fr) * 2008-02-06 2011-03-11 Sanofi Aventis Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme
FR2952823B1 (fr) * 2009-10-30 2012-04-20 Sanofi Aventis Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR2951945B1 (fr) 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
FR2961209B1 (fr) * 2010-06-11 2013-03-01 Sanofi Aventis Procede de synthese de la ferroquine par amination reductrice convergente.
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
CN105250295B (zh) * 2014-07-07 2018-12-25 广州中医药大学科技产业园有限公司 一种联合用药物及其作为免疫调节剂的应用
US10512652B2 (en) 2015-07-20 2019-12-24 University Of Vermont And State Agricultural College Use of cymanquine compounds as antimalarial agents
CN107802755A (zh) * 2017-11-08 2018-03-16 江西龙卿堂科技有限公司 一种具有防蚊防疟作用的青蒿软膏
KR102073961B1 (ko) * 2018-11-16 2020-02-05 (주)프론트바이오 메트포르민 및 페로센계 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
CN115803021B (zh) * 2020-07-09 2025-04-18 法国诗华大药厂 用于预防和/或治疗利什曼病的兽医学组合物
TW202220645A (zh) * 2020-08-14 2022-06-01 印度商太陽製藥工業有限公司 用於治療瘧疾的固定劑量組合藥物
WO2022231238A1 (fr) * 2021-04-26 2022-11-03 심민보 Composition pharmaceutique contenant de l'artésunate ou un sel de celui-ci et de la pyronaridine ou un sel de celle-ci, utilisée à des fins antipyrétiques, anti-inflammatoires, antivirales et pour le traitement ou la prévention de la covid-19, et procédé l'utilisant
CN113952360B (zh) * 2021-09-14 2023-03-10 上海交通大学 一种亚铁离子在治疗疟疾的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN166154B (fr) * 1987-05-08 1990-03-24 Hoechst India
BRPI0413767A (pt) * 2003-09-04 2006-10-31 Cipla Ltd produto farmacêutico ou formulação farmacêutica, processo para preparar um produto farmacêutico ou formulação farmacêutica, método para tratar um doença e uso de pelo menos uma artemisinina ou um sal, solvato ou derivado desta

Also Published As

Publication number Publication date
AU2006238506B2 (en) 2012-03-01
ZA200708800B (en) 2009-01-28
EA200702282A1 (ru) 2008-02-28
DOP2006000092A (es) 2006-11-15
AP2007004211A0 (en) 2007-10-31
PA8669801A1 (es) 2006-11-09
FR2884715B1 (fr) 2007-06-15
US20120258945A1 (en) 2012-10-11
PE20110119A1 (es) 2011-03-08
HN2006015130A (es) 2010-08-19
SG161270A1 (en) 2010-05-27
BRPI0610851A2 (pt) 2010-08-03
TNSN07359A1 (en) 2008-12-31
GT200600157A (es) 2006-11-07
CR9425A (es) 2008-02-20
KR20080009088A (ko) 2008-01-24
MX2007012645A (es) 2007-12-13
AR054253A1 (es) 2007-06-13
UA96414C2 (ru) 2011-11-10
CN101163470A (zh) 2008-04-16
NZ562117A (en) 2010-01-29
CA2605385A1 (fr) 2006-10-26
PE20061314A1 (es) 2006-12-27
TW200716092A (en) 2007-05-01
IL186048A0 (en) 2008-02-09
MY145581A (en) 2012-02-29
EP1874293A1 (fr) 2008-01-09
AP2782A (en) 2013-10-31
EA012630B1 (ru) 2009-10-30
FR2884715A1 (fr) 2006-10-27
WO2006111647A1 (fr) 2006-10-26
JP5148478B2 (ja) 2013-02-20
NO20075920L (no) 2007-11-16
AU2006238506A1 (en) 2006-10-26
JP2008536900A (ja) 2008-09-11
CN102836163A (zh) 2012-12-26
TWI387456B (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
LU92853I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
WO2004047838A3 (fr) Composition pharmaceutique a base d'agonistes des recepteurs beta-3-adrenergiques et d'antimuscariniques
MA29871B1 (fr) Composition pharmaceutique concue pour ameliorer la fonction cognitive
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BG105302A (en) Means for improving cognition
TNSN07359A1 (en) Association between ferroquine and an artemisinine derivative for treating malaria
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MY148125A (en) Compounds
EP1254668A3 (fr) Combinaison d'un inhibiteur de la recapture de la sérotonine et d'un GABA-A alpha 2/3 agoniste pour l'utilisation dans l'anxiété et la dépression
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
FR2869539A1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
CA2353808A1 (fr) Agent permettant d'abaisser les niveaux d'endotheline
WO2001045682A3 (fr) Formulations d'agonistes de l'adenosine a1